ATLANTA, GA – – (ACCESSWIRE – October 27, 2022) – – Holzer & Holzer, LLC is investigating whether Accelerate Diagnostics, Inc. (“Accelerate Diagnostics” or the “Company”) (NASDAQ: AXDX) complied with federal securities laws. On October 21, 2022, Accelerate Diagnostics announced that it was required by the FDA to obtain 510(k) clearance for its Accelerate Arc Products, discontinue US marketing and distribution of those products, and revise/remove the Company’s registration and listing of those products as Class I devices. Following this announcement, the Company’s stock price dropped.
If you purchased Accelerate Diagnostics stock and suffered a loss on that investment, you are encouraged to contact Corey Holzer, Esq. at firstname.lastname@example.org or Joshua Karr, Esq. at email@example.com, call our toll-free number at (888) 508-6832, or visit our website at https://holzerlaw.com/case/accelerate-diagnostics/ to discuss your legal rights.